May 2004
Worldwide Biotech;May2004, Vol. 16 Issue 5, p7
Trade Publication
Focuses on the medicinal chemistry collaboration between Evotec OAI AG and Panacos Pharmaceuticals Inc. Information on Panacos' clinical trials on PA-457 HIV drug; Business strategy of Evotec; Proprietary discovery technologies of Panacos.


Related Articles

  • Evotec uses collaborations to supplement pipeline.  // PharmaWatch: CNS;May 2004, Vol. 3 Issue 5, p6 

    Reports on the collaboration of Evotec OAI AG and Panacos Pharmaceuticals Inc. to develop and market a patent portfolio. Design and optimization of novel anti-HIV compounds; Initiation of a phase I clinical trials of Panacos' small molecule intended to treat HIV infection; Efficacy of the drug...

  • Panacos Sheds 62% On Latest Phase IIb Data For Bevirimat. Morris, Trista // BioWorld Today;12/12/2007, Vol. 18 Issue 240, p1 

    The article reports that the preliminary data from Panacos Pharmaceuticals Inc.'s latest Phase IIb trial with HIV drug bevirimat have caused the company's shares to fall 61.7 percent. The data indicated a lower mean viral load reduction and fewer responders with the 350-milligram solution of...

  • Panacos: developing the antiretroviral armory.  // PharmaWatch: Monthly Review;Oct2005, Vol. 4 Issue 10, p34 

    The article reports that Phase IIa data published by Panacos Pharmaceuticals Inc. has revealed that the company's lead HIV compound, PA-457, met the trial's primary endpoint. As such, the maturation inhibitor has moved a step closer to being able to provide a new option for patients resistant to...

  • Deal watch: NR2B antagonist pursued for treatment-resistant depression.  // Nature Reviews Drug Discovery;May2009, Vol. 8 Issue 5, p349 

    The article reports on the drug development agreement between F. Hoffmann La-Roche Ltd. and Evotec AG, wherein Roche will fund the Phase II clinical development of a selective N-methyl-d-aspartate receptor antagonist, EVT 101, for patients with treatment-resistant depression. It mentions that...

  • MARYLAND: Penacos Pharma gets fast-track status for HIV drug.  // Gay & Lesbian Times;1/20/2005, Issue 891, p30 

    Reports that Panacos Pharmaceuticals Inc. has received fast-track status from the U.S. Food and Drug Administration for PA, 457, the company's oral drug candidate for HIV. Aim of the fast-track status to expedite development and approval of new drugs that may have the potential to improve...

  • CLINIC ROUNDUP.  // BioWorld Today;2/29/2008, Vol. 19 Issue 41, p2 

    The article presents updates on several clinical trials. The study of ANA773 agonist prodrug from Anadys Pharmaceuticals Inc. is designed to identify pharmacologically active doses and preliminary antitumor activity. Positive results were announced by Athersys Inc. from its trial of ATHX-105 for...

  • Spermatech, Evotec to Screen Target for Male Contraceptive. Sheridan, Cormac // BioWorld International;3/19/2008, Vol. 13 Issue 12, p2 

    The article reports that Evotec AG has been chosen as the partner of Spermatech AS, an early stage Norwegian firm developing a non-hormonal male contraceptive pill, for a high-throughput screening and lead discovery project against a novel target associated with regulating sperm motility. The...

  • Evotec Shares Rise On Kidney Disease Pact with Astrazeneca. Sheridan, Cormac // BioWorld Today;10/23/2013, Vol. 24 Issue 204, p1 

    The article reports that shares in Evotec AG rose 10 percent on October 21, 2013 on news of a research partnership with Astrazeneca plc on the development of disease-modifying drugs for chronic kidney diseases. It informs that while the financial terms were not disclosed, Evotec will receive an...

  • Evotec gets Milestone as Boehringer Starts Phase I.  // Worldwide Biotech;Jul2011, Vol. 23 Issue 7, p3 

    The article reports that Evotec will be given 2 million euros as pharmaceutical company Boehringer Ingelheim starts its Phase I clinical test. The partnership between Evotec and Boehringer seeks to create a compound that fights neuropathic pain, which occurs due to a malfunction or damage to the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics